The TRIUMPH-1 results are global news, but they have specific implications for Canadians watching this drug’s progress. Here’s what the data means in a Canadian context.
How this changes the Canadian approval timeline
Before TRIUMPH-1, retatrutide was an interesting Phase 2 drug with promising but unconfirmed data. After these results — 30.3% mean weight loss in a Phase 3 trial — it becomes one of the most anticipated regulatory submissions in metabolic medicine.
The path to Health Canada approval now looks clearer:
- Remaining Phase 3 data: TRIUMPH-2 (type 2 diabetes), TRIUMPH-3 (cardiovascular outcomes), TRIUMPH-5 (head-to-head vs semaglutide) still need to report. A positive body of evidence across multiple populations strengthens any regulatory submission.
- New Drug Submission (NDS): If the full dataset is positive, Eli Lilly can file an NDS with Health Canada’s Therapeutic Products Directorate. Review timelines vary but typically take 12–18 months for priority drugs.
- Notice of Compliance (NOC): Health Canada issues an NOC if the drug is found safe, efficacious, and of high quality. This is the moment retatrutide becomes prescribable in Canada.
- Provincial coverage: Even after NOC, each province evaluates coverage through its own drug plan (e.g., Ontario Drug Benefit, BC PharmaCare). Private insurers may cover it sooner, but coverage is not guaranteed.
Realistic estimate: If everything proceeds on an accelerated timeline, retatrutide could be approved in Canada sometime in 2027. This is not a confirmed date — it depends on trial results and regulatory review.
Canadian clinical trial participation
TRIUMPH-1 listed 9 Canadian trial sites. The broader TRIUMPH program has sites across the country:
- TRIUMPH-OUTCOMES (NCT06383390): 22 Canadian sites — the largest Canadian presence of any retatrutide trial
- TRIUMPH-2 (NCT05929079): Canadian sites included
- TRIUMPH-5 vs semaglutide (NCT06260722): 12 Canadian sites
Canadian participation in these trials means Health Canada reviewers will have data from local populations, which can support the approval and reimbursement case.
What Canadian healthcare providers are watching
The 30.3% weight loss figure has drawn comparisons to bariatric surgery — a comparison that matters in Canada’s publicly-funded system. Bariatric surgery wait times in some provinces exceed 2–3 years. A drug that approaches surgical-level weight loss could change treatment algorithms, but only if:
- Long-term safety data (TRIUMPH-3 CVOT running through 2029) supports chronic use
- Cost-effectiveness analyses justify public reimbursement
- Supply chains can meet demand (supply constraints have affected tirzepatide and semaglutide availability in Canada)
Sources
- Eli Lilly press release — TRIUMPH-1 results
- ClinicalTrials.gov — TRIUMPH-1 (NCT05929066)
- ClinicalTrials.gov — TRIUMPH-OUTCOMES (NCT06383390)
- Health Canada — Drug Review Process
This article provides educational analysis only. Approval timelines are estimates based on publicly available information and are not confirmed by Eli Lilly or Health Canada.